ReviewJournal of inflammation research2026
Short-Chain Fatty Acids: A Key Modulator of Sepsis-Associated Acute Respiratory Distress Syndrome.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Childhood asthma and the microbiome: from gut-lung axis mechanisms to precision prevention strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated acute respiratory distress syndrome (ARDS) is a common clinical fatal complication, and intestinal flora imbalance has been proved to be a key link in the mechanism of morbidity. Intestinal dysbacteriosis directly contributes to lung injury through mechanisms such as microbial translocation, systemic inflammation, and immune dysregulation, and depletion of short-chain fatty acids (SCFAs) as key protective metabolites is an important driver of ARDS progression. SCFAs, mainly including acetate, propionate and butyrate, exert anti-inflammatory, immunomodulatory and barrier protective effects by inhibiting histone deacetylase (HDACs) and activating G protein-coupled receptors (GPCRs). However, SCFAs also exhibit concentration, type, and inflammation stage-dependent bidirectional regulatory properties. Clearly defining this bidirectional regulation is a critical factor for precision dosing and personalized therapies in a clinical setting. This article systematically reviews the causal mechanism of ARDS caused by intestinal flora imbalance, the bidirectional regulation of SCFAs, and the intervention strategies based on intestinal flora, providing new ideas for the precise treatment of sepsis-associated ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.